Essity AB: Strong Growth and Opportunity for Investors
Essity AB, a global leader in hygiene and health products, is demonstrating robust growth with optimized revenue and profit forecasts for 2026 and 2027. The company’s focus on personal care and paper hygiene is proving successful, benefiting from increasing demand in the sector. Investors, particularly those in the DACH region (Germany, Austria, and Switzerland), are finding value in Essity’s stable dividend policy and strong European sales.
Financial Outlook for 2026 and 2027
Essity has reassured investors with updated forecasts for the coming years. Estimates project revenues of approximately SEK 137 billion in 2026 and SEK 141 billion in 2027. Net profit is expected to reach SEK 12.62 billion in 2026 and increase to SEK 13.7 billion in 2027. This translates to a price-to-earnings (P/E) ratio of 14.2x, highlighting the resilience of the hygiene sector.
Strategic Importance of the European Market
Europe represents 60% of Essity’s sales, making the stock a stable anchor in uncertain markets, particularly for investors in the DACH region. Brands like Zewa and Tempo are well-established in these markets.
Key Business Segments
Essity’s portfolio is diversified across three main segments:
- Human Care (54.2% of sales): Includes brands like Tena for incontinence, Libresse for feminine protection, and Libero for diapers.
- Paper Hygiene (26.1% of sales): Features brands such as Tempo, Zewa, and Lotus.
- Professional Hygiene (19.7% of sales): Offers soaps and disinfectants.
Upcoming Annual General Meeting
Essity’s Annual General Meeting will be held on Thursday, March 26, 2026, at 2 p.m. At Stockholm Waterfront Congress Centre, Stockholm. Shareholders can participate in person, by proxy, or through advance voting. The deadline to register for participation or submit advance votes is Friday, March 20, 2026.
Recent Developments
- Essity completed the acquisition of a feminine care business from Edgewell Personal Care Company in February 2026.
- The company announced executive changes, with Ulrika Kolsrud appointed as CEO, effective June 1, 2025.
- Essity initiated an equity buyback plan for 60,946,249 shares, representing 8.79% of its issued share capital.
Analyst Expectations
Analysts forecast earnings and revenue growth of 4.9% and 2% per annum, respectively, with earnings per share (EPS) expected to grow by 5.5% annually. Return on equity is projected to be 14.4% in three years.
Dividend Information
Essity offers a dividend of SEK 8.75 with an ex-dividend date of March 27th.
Keep reading
- UCLA Scientists Engineer Cord Blood T Cells to Target Hidden Solid Tumors
- Flu and COVID-19 Twindemic Ahead of Chuseok: Prevention Tips for High-Risk Groups
- Stock futures fall as investors weigh AI safety concerns, oil gains: Live updates (newsylist.com)
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)